3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Lung Neoplasms
1
Interventions
pembrolizumab
18
Cyclophosphamide
9
fludarabine
8
Nivolumab
8
cemiplimab
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Filgrastim
4
Drug Therapy
4
Docetaxel
4
Cisplatin
4
palbociclib
3
durvalumab
3
Paclitaxel
3
Interleukin-2
3
Bortezomib
3
fludarabine phosphate
2
epacadostat
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Temozolomide
2
SS1(dsFv)PE38
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Interleukin-12
×
Gynecologic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled